Clinical Trials Logo

Filter by:
NCT ID: NCT05633862 Completed - Healthy Clinical Trials

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Start date: January 13, 2023
Phase: Phase 1
Study type: Interventional

The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.

NCT ID: NCT05633524 Completed - Sjögren's Syndrome Clinical Trials

HRR as a Novel Biomarker in Sjögren's Syndrome

Start date: October 29, 2020
Phase:
Study type: Observational

Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eye (xerophthalmia) sensation (1). Although dry mouth and dry eye are the main symptoms, the disease may influence many organs and systems. Diagnosis is made with ocular surface staining scores, anti-SS-A/SS-B auto-antibody positivity, and minor salivary gland biopsy (2). The Complete blood count (CBC) is a simple, inexpensive, accessible, and routinely used laboratory parameter that can be linked to oxidative stress, inflammation and microvascular flow resistance. Parameters include NLR and PLR values may be calculated by using CBC parameters (3). Neutrophil/lymphocyte ratio is used as an inflammatory marker in the diagnosis and prognosis of many cardiovascular diseases, malignancies, and infections (4-6). Peripheral inflammatory biomarkers of hematologic indices had been suggested by numerous studies to play a role during SS onset and progression.

NCT ID: NCT05631782 Completed - Hemodialysis Clinical Trials

Effects of Shenkang Decoction on Creatinine and Blood Urea Nitrogen in Chronic Renal Failure Hemodialysis Patients

Start date: November 10, 2020
Phase: Early Phase 1
Study type: Interventional

To explore the clinical effect of Shenkang Decoction in chronic renal failure (CRF) patients with hemodialysis (HD).

NCT ID: NCT05631678 Completed - Clinical trials for Locally Advanced or Metastatic NSCLC

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Start date: June 6, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects. To evaluate the safety of ASK120067 tablets or combination with rifampicin capsules or itraconazole capsules in healthy subjects.

NCT ID: NCT05631470 Completed - Stroke, Ischemic Clinical Trials

Diagnostic Accuracy for Hemodynamically ICAS of MR-FFR Comparing With Pressure-wire-based FFR.

Start date: June 18, 2019
Phase:
Study type: Observational

The aim of this study was to determine the diagnostic accuracy of MR-FFR to detect functionally significant ICAS comparing with pressure-wire-based FFR.

NCT ID: NCT05631145 Completed - Depression, Anxiety Clinical Trials

MT Combined With XKSA for Depressive Symptoms During COVID-19

Start date: May 3, 2020
Phase: N/A
Study type: Interventional

Social isolation related mental health problems have raised many concerns during the COVID-19 outbreaks. Mental health care for people in quarantined hotels is in urgent need, but concrete program is rarely reported. Morita therapy and acupressure have been identified as effective treatments for regulating mood and sleep. The study aimed to examine whether Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA) could improve depressive, anxiety symptoms and sleep quality in isolated people with depressive symptoms.

NCT ID: NCT05631028 Completed - Lung Cancer Clinical Trials

95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

General anesthesia with double-lumen endobronchial tubes intubation is the main anesthesia method in thoracic surgery.However, double-lumen endobronchial tubes intubation can produce greater stimulation and cause more cardiovascular reactions, and the ideal anesthetic drugs can effectively reduce adverse reactions.Remimazolam is a new type of benzodiazepine drug that can be safely used for the induction and maintenance of general anesthesia, and it is an ideal and short-acting anesthetic alternative.As the new drug has had a short clinical entry time.There are few clinical data in all aspects, so it is necessary to clarify its rational use in the induction of anesthesia.Dexmedetomidine is a highly selective α 2 adrenergic receptor agonist, and it is currently the most popular adjunct to clinical anesthesia.However, the clinical data of anesthesia induction by dexmedetomidine combined with Remimazolam are rarely reported. In the case of prior use of dexmedetomidine, to explore 50% effective dose (ED50) and ED95 of Remimazolam for the induction of anesthesia to inhibit the cardiovascular response of double-lumen bronchial intubation, in order to provide more data for the rational use of remimazolam and a reference for clinical rational drug use.

NCT ID: NCT05630573 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

Start date: October 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profile of TNM001 injection in healthy preterm and term infants. The main questions it aims to answer are: - the safety and tolerability of TNM001 injection - the pharmacokinetic (PK) profile of TNM001

NCT ID: NCT05629949 Completed - Breast Cancer Clinical Trials

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Start date: April 29, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of QL1701 and Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.

NCT ID: NCT05629403 Completed - Clinical trials for Gestational Diabetes

Exclusive Breastfeeding Improves Puerperal Glucose Metabolism in Pregnant Women With Gestational Diabetes Mellitus and Links to Lipids Composition

Start date: September 1, 2021
Phase:
Study type: Observational

Breastfeeding could effectively be associated with a lower risk of future type 2 diabetes (T2D) in women with gestational diabetes mellitus (GDM), but the short-term protective impact of puerperal breastfeeding on maternal metabolic recovery of GDM women remains unascertained. The investigators recruited GDM participants at 6-9 weeks postpartum and retrieved clinical diagnoses of GDM from electronic medical records. Feeding patterns were collected via phone calls. Glucose metabolism parameters and lipid profiling were performed on fasting plasma samples collected from patients 6-9 weeks postpartum (20 breastfeeding cases vs. 15 formula feeding cases).